Welcome to our dedicated page for GSK PLC SEC filings (Ticker: GSK), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
From breakthrough shingles vaccines to ViiV Healthcare’s HIV therapies, GSK’s science generates disclosures as complex as its pipeline. If you have ever wondered where the RSV launch costs are buried or how respiratory revenues move the needle, this page brings every document together and answers the questions people actually ask, like “GSK SEC filings explained simply� and “GSK insider trading Form 4 transactions.�
Stock Titan applies AI reading models to each new 20-F, 6-K, or proxy so you can skim instead of sift. Need the GSK quarterly earnings report 10-Q filing or an 8-K material events explained summary? You’ll see real-time alerts, plain-English highlights of vaccine safety data, and side-by-side comparisons of R&D spending. Our platform flags GSK Form 4 insider transactions real-time, traces option grants in the GSK proxy statement executive compensation section, and links each note to the relevant page in the PDF.
Whether you’re tracking patent-cliff timing, modelling Shingrix margins, or verifying GSK executive stock transactions Form 4, you’ll find everything here:
- Annual report 10-K simplified views (alongside the official 20-F)
- AI context for 6-K interim results and GSK earnings report filing analysis
- Instant download of exhibits that disclose trial halts, divestitures, or supply agreements
GSK announced that the US FDA has accepted for priority review a supplemental New Drug Application for gepotidacin as an oral treatment for uncomplicated urogenital gonorrhoea in patients aged 12 years and older (weighing �45 kg), with a Prescription Drug User Fee Act action date set for December 2025. The submission is supported by the EAGLE-1 phase III trial published in The Lancet, where oral gepotidacin (two doses of 3,000 mg) achieved a 92.6% success rate at the urogenital site (187/202) versus 91.2% (186/204) for intramuscular ceftriaxone plus oral azithromycin, meeting non-inferiority. No failures from bacterial persistence were reported and no serious drug-related adverse events were observed; the most common adverse reactions were mild to moderate gastrointestinal events. Gepotidacin previously received US approval as Blujepa for uncomplicated urinary tract infection and its development was funded in part by BARDA and the US Department of Defense.
GSK plc completed a tranche of its announced share buyback on 08 August 2025, purchasing 497,923 ordinary shares at prices between 1,389.50p and 1,405.50p, with a volume-weighted average price of 1,397.58p. The shares were bought through Merrill Lynch International under the non-discretionary broker agreement entered into on 4 June 2025 and will be held as Treasury shares. Since 4 June 2025 the company has purchased 21,908,567 ordinary shares under this programme.
Following this purchase GSK will hold 240,042,950 ordinary shares in treasury and have 4,075,348,296 ordinary shares in issue (excluding Treasury shares). The company states the total number of voting rights is 4,075,348,296, and that ordinary shares held in treasury represent 5.89% of voting rights for DTR calculation purposes.
GSK has monetised its licence with CureVac through a settlement linked to CureVac’s 7 Aug 2025 agreement with BioNTech. The company will receive an immediate $370 million payment ($320 m cash) and collect a 1 % royalty on all 2025-onward US sales of Pfizer/BioNTech influenza, COVID-19 and combination mRNA vaccines.
The settlement also amends the CureVac licence, materially reducing future royalties that GSK would owe on its own mRNA pipeline products.
- Contingent upside: if BioNTech’s proposed acquisition of CureVac closes, GSK gains an extra $130 m cash, a further 1 % royalty on ex-US sales of the same vaccines and lower milestone obligations.
- Accounting: the $370 m is booked as other operating income (adjusting item) in Q3-2025; future royalties flow through total & core results.
- Litigation: GSK’s separate patent suits against Pfizer/BioNTech continue in the US and Europe.
- Strategic: GSK will tender its �16.6 m CureVac shares under the forthcoming offer.
The deal delivers near-term cash, creates recurring high-margin royalty streams and lowers eventual COGS for GSK’s own mRNA vaccines, though additional proceeds depend on the CureVac acquisition closing and legal uncertainties persist.
GSK plc filed a Form 6-K disclosing the latest tranche of its ongoing share buy-back programme. On 7 August 2025 the company repurchased 502,466 ordinary shares (31¼ p nominal) through Merrill Lynch International at prices between 1,361.00 p and 1,385.50 p, delivering a volume-weighted average price of 1,376.94 p.
These shares will be held in treasury, lifting treasury holdings to 239,545,027 shares, equal to 5.88 % of total voting rights. Shares in issue ex-treasury now stand at 4,075,843,458. Since the non-discretionary agreement with the broker began on 4 June 2025, GSK has acquired 21,410,644 shares under the programme.
The disclosure provides investors with the denominator for holdings notifications under UK Listing Rule DTR 5 and confirms that the buy-back remains within the previously announced authorisation.
GSK plc reports that, under its existing share buyback programme, it repurchased 498,759 ordinary shares (31¼p nominal) on 05 Aug 2025 through Merrill Lynch International at prices between 1,388.00±èâ€�1,412.50±è, producing a VWAP of 1,397.84p. The shares will be held in treasury.
Since the non-discretionary mandate began on 4 Jun 2025, GSK has bought back 20,404,162 shares. Following the latest purchase the company now holds 238,538,545 treasury shares and has 4,076,849,940 ordinary shares in issue excluding treasury. Treasury shares account for 5.85 % of total voting rights, leaving 4,076,849,940 voting rights outstanding.
The filing provides trading-venue detail for compliance with FCA Disclosure Guidance & Transparency Rules and updates investors� denominator for any shareholding notification requirements.
GSK plc has filed a Form 6-K to meet Financial Conduct Authority (FCA) Disclosure Guidance & Transparency Rule 5.6.1R. As of 31 July 2025 the company had 4,315,385,410 issued Ordinary Shares of 31 ¼ pence each. Of these, 237,044,421 shares were held in treasury, leaving 4,078,340,989 voting rights in circulation. Shareholders should use this denominator when calculating threshold notifications of holdings under FCA rules. The notice was authorised by Company Secretary V. A. Whyte and filed on 1 August 2025.
GSK plc filed a Form 6-K detailing a routine share repurchase executed on 31 July 2025 under its June-2025 non-discretionary buy-back mandate.
- Shares bought: 474,100 ordinary shares (nominal 31¼ p).
- Price range: 1,404.50â€�1,461.00&²Ô²ú²õ±è;³Òµþ±è; VWAP 1,423.11 GBp.
- Cumulative purchases since 4 June 2025: 18,910,038 shares.
The shares will be held in treasury, increasing the treasury balance to 237,044,421. Shares in issue (excluding treasury) now total 4,078,340,989, establishing the new denominator for voting-rights disclosures. Treasury stock represents 5.81 % of total voting rights.
No operational, earnings or guidance updates were provided; the filing primarily fulfils UK DTR 5.5.1R disclosure requirements.
FAQ
What is the current stock price of GSK PLC (GSK)?
What is the market cap of GSK PLC (GSK)?
